Literature DB >> 9183513

Targeted naltrexone treatment of early problem drinkers.

H R Kranzler1, H Tennen, C Penta, M J Bohn.   

Abstract

Naltrexone is approved for daily use in the treatment of alcohol dependence. We evaluated the feasibility of using targeted naltrexone (i.e., on an "as-needed" basis) to treat early problem drinkers. Twenty-one subjects (52% male) received brief coping skills training weekly for 4 weeks, along with naltrexone (50 mg), which they were instructed to use 2 to 5 times per week in anticipation of high-risk drinking situations. During treatment, statistically and clinically significant declines were observed across a variety of drinking-related outcomes, including the intensity of drinking, the decline in which was correlated with medication use. Beneficial effects of the intervention were still evident during the 3-month posttreatment period. Further research, including a placebo-controlled evaluation of targeted naltrexone, is needed to determine the optimal treatment strategy for early problem drinkers, many of whom are seen in the primary-care medical setting.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9183513     DOI: 10.1016/s0306-4603(96)00064-0

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  13 in total

Review 1.  Targeted opioid receptor antagonists in the treatment of alcohol use disorders.

Authors:  Mark J Niciu; Albert J Arias
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

2.  Longitudinal findings from a randomized clinical trial of naltrexone for young adult heavy drinkers.

Authors:  Kelly S DeMartini; Ralitza Gueorguieva; Robert F Leeman; William R Corbin; Lisa M Fucito; Henry R Kranzler; Stephanie S O'Malley
Journal:  J Consult Clin Psychol       Date:  2015-12-14

3.  A pilot study of naltrexone and BASICS for heavy drinking young adults.

Authors:  Robert F Leeman; Rebekka S Palmer; William R Corbin; Denise M Romano; Boris Meandzija; Stephanie S O'Malley
Journal:  Addict Behav       Date:  2008-04-13       Impact factor: 3.913

Review 4.  Pharmacotherapy of alcohol use disorders: seventy-five years of progress.

Authors:  Leah R Zindel; Henry R Kranzler
Journal:  J Stud Alcohol Drugs Suppl       Date:  2014

5.  Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.

Authors:  Stephanie S O'Malley; William R Corbin; Robert F Leeman; Kelly S DeMartini; Lisa M Fucito; Jolomi Ikomi; Denise M Romano; Ran Wu; Benjamin A Toll; Kenneth J Sher; Ralitza Gueorguieva; Henry R Kranzler
Journal:  J Clin Psychiatry       Date:  2015-02       Impact factor: 4.384

6.  A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking.

Authors:  Janice C Froehlich; Stephen M Fischer; Emily R Nicholson; Julian E Dilley; Nicholas J Filosa; Teal N Smith; Logan C Rademacher
Journal:  Alcohol Clin Exp Res       Date:  2017-02-09       Impact factor: 3.455

7.  Acute baclofen diminishes resting baseline blood flow to limbic structures: a perfusion fMRI study.

Authors:  Teresa R Franklin; Joshua Shin; Kanchana Jagannathan; Jesse J Suh; John A Detre; Charles P O'Brien; Anna Rose Childress
Journal:  Drug Alcohol Depend       Date:  2012-04-17       Impact factor: 4.492

8.  Pharmacoprophylaxis of alcohol dependence: Review and update Part II: Efficacy.

Authors:  Sandeep Grover; Debasish Basu; Gaurav Bhateja
Journal:  Indian J Psychiatry       Date:  2007-01       Impact factor: 1.759

Review 9.  Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; George A Kenna
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

10.  Specific and nonspecific effects of naltrexone on goal-directed and habitual models of alcohol seeking and drinking.

Authors:  Rachel A Hay; Joshua H Jennings; Dawnya L Zitzman; Clyde W Hodge; Donita L Robinson
Journal:  Alcohol Clin Exp Res       Date:  2013-02-07       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.